GLP-1 drug for polycystic kidney disease and weight
Treatments studied
Part of Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a GLP-1 receptor agonist (a type of medicine that helps with weight and metabolism) in people with polycystic kidney disease who are overweight. It aims to see if this drug can help slow kidney disease progression.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with ADPKD (autosomal dominant polycystic kidney disease).
- Your body mass index (BMI) is 27 or higher.
- Your kidney function (eGFR) is at least 30 mL/min/1.73m².
- You have not had diabetes, pancreatitis, or certain thyroid conditions.
- You are not currently using tolvaptan or participating in another weight loss program.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a GLP-1 receptor agonist (a type of diabetes medication) can improve fat tissue health in people with chronic kidney disease who also have type 2 diabetes, cardiovascular disease, or obesity. It may help protect your kidneys and overall health.
This study tests a medication called tirzepatide for people with type 1 diabetes who also have overweight or obesity. Tirzepatide may help with weight loss and blood sugar control, and you'll use a continuous glucose monitor throughout the study.
This study tests a medicine called tirzepatide to see if it helps people with overweight or obesity lose weight, whether or not they also have type 2 diabetes. Tirzepatide is given as an injection and works on hormones that control appetite.
This study tests a medication called tirzepatide (a once-weekly injection) to help teenagers with obesity and related health conditions lose weight. It aims to see if the drug is safe and effective for this age group.
This Phase 2 study tests whether tirzepatide can improve how your body handles fat (especially in people with overweight or obesity) and reduce fat-related “lipotoxicity.” It may help with body fat function and related health markers, but you must meet specific health and medication rules.
This study tests a weekly injection called tirzepatide to help people with obesity lose weight. It will be done at Hospital de Clínicas in Paraguay and lasts about 12 months.
Hear when a new Autosomal Dominant Polycystic Kidney trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.